Prison-Based HIV Partner Notification (APN vs. self-notification)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Incarcerated men with HIV are randomized to either standard self-notification or an assisted partner notification (APN) approach called Impart. The APN group can have specially trained staff confidentially notify partners or have the index participant tell partners by phone or in person. Outcomes after six weeks compare how many partners are notified, tested for HIV, diagnosed, and linked to care in each group. After six weeks, outreach-assisted notification is offered to those who initially notified partners themselves. The study aims to assess whether prison-based APN increases partner testing and linkage to treatment while reducing barriers to notification.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* HIV-diagnosed
* Sexually active (penile-vaginal or penile-anal) and/or sharing injection equipment during the year before incarceration

Exclusion Criteria:

* Incarcerated more than 5 years

Where it's running

• Fakultas Ilmu Keperawatan, Universitas Indonesia
  Depok, West Java, Indonesia Recruiting

Study contacts

• Principal investigator: Agung Waluyo, PhD — Universitas Indonesia
• Study coordinator: Gabriel Culbert, PhD
• Email: gculbert@uic.edu
• Phone: 312-996-1627

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Project SHIELD 2.0: Police Education to Support Public Health in Kentucky

  Aimed at police in Kentucky, this program tests whether SHIELD training given to officers, with health workers helping deliver it, can reduce drug-related arrests and steer people who use drugs toward MOUD and other health services.

  Recruiting Johns Hopkins Bloomberg School of Public Health · Lexington, Kentucky · NCT07804121

• New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV

  This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.

  Recruiting Indiana University · Lilongwe · NCT07793006

• Bridge to Belonging: A Peer‑Led Program to Reduce Loneliness and Depression in older gay and bisexual men with HIV

  This program tests a peer-delivered, manualized approach to help men aged 50+ with HIV connect to LGBTQ+-affirming elder services to see if it reduces loneliness and depressive symptoms.

  Recruiting Fenway Community Health · Boston, Massachusetts · NCT07762066

• HIV vaccine test in healthy adults using CH505 nanoparticles and mRNA boosters

  This early-stage study will test the safety and immune responses of CH505 vaccine regimens in healthy adults to see if they can trigger HIV-specific immune protection.

  Recruiting at 2 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · San Francisco, California and 7 other locations · NCT07757802

• Stigma-reducing program to help women who use drugs stay in HIV care

  This test checks whether a stigma-reduction program helps women living with HIV who use drugs stay engaged in HIV care in Ukraine.

  Recruiting Johns Hopkins Bloomberg School of Public Health · Kyiv, Kyiv Oblast · NCT07751978

• Platelets and HIV Reservoirs: A look at how platelets might harbor HIV in people living with HIV

  This observational study tests whether HIV can be found inside platelets in adults with suppressed HIV on therapy.

  Recruiting Tourcoing Hospital · Tourcoing · NCT07745530

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.